Nanobiotix
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
NANO | PA
Overview
Corporate Details
- ISIN(s):
- FR0010102145 (+2 more)
- LEI:
- 969500667RSYIH8YL895
- Country:
- France
- Address:
- 60 RUE DE WATTIGNIES, 75012 PARIS
- Website:
- https://www.nanobiotix.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Nanobiotix is a late-stage clinical biotechnology company pioneering the development and commercialization of physics-based nanotherapeutics. The company's lead candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. It works by amplifying the dose and efficacy of radiotherapy within cancer cells, aiming to enhance tumor destruction while sparing surrounding healthy tissue. This approach may also prime an immune response against metastatic tumors. Nanobiotix has a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, to co-develop and commercialize NBTXR3, with an initial focus on head, neck, and lung cancers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-12 19:00 |
Declaration of Voting Results & Voting Rights Announcements
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS …
|
French | 112.2 KB | ||
| 2025-09-12 19:00 |
Declaration of Voting Results & Voting Rights Announcements
Voting Rights and Shares Capital of the Company
|
English | 113.6 KB | ||
| 2025-09-02 22:15 |
Regulatory News Service
Nanobiotix participera à la conférence investisseurs annuelle H.C. Wainwright g…
|
French | 93.9 KB | ||
| 2025-09-02 22:15 |
Regulatory News Service
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment …
|
English | 69.0 KB | ||
| 2025-08-11 11:29 |
Major Shareholding Notification
Franchissements de seuils
|
French | 111.3 KB | ||
| 2025-07-11 11:18 |
Major Shareholding Notification
Franchissement de seuils
|
French | 123.4 KB | ||
| 2025-07-11 11:11 |
Major Shareholding Notification
Franchissement de seuils
|
French | 122.5 KB | ||
| 2025-06-20 15:17 |
Major Shareholding Notification
Franchissement de seuils
|
French | 123.1 KB | ||
| 2025-06-20 15:07 |
Major Shareholding Notification
Franchissement de seuils
|
French | 123.4 KB | ||
| 2025-06-10 22:15 |
Declaration of Voting Results & Voting Rights Announcements
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 110.8 KB | ||
| 2025-06-10 22:15 |
Declaration of Voting Results & Voting Rights Announcements
Voting Rights and Shares Capital of the Company
|
English | 112.0 KB | ||
| 2025-05-28 08:00 |
Regulatory News Service
NANOBIOTIX participera à la conférence investisseurs annuelle Jefferies Global …
|
French | 91.4 KB | ||
| 2025-05-28 08:00 |
Regulatory News Service
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
|
English | 88.9 KB | ||
| 2025-05-21 22:15 |
Regulatory News Service
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
|
English | 173.9 KB | ||
| 2025-05-21 22:15 |
Earnings Release
Nanobiotix fait le point sur sa trésorerie et son activité opérationnelle du p…
|
French | 194.9 KB |
Automate Your Workflow. Get a real-time feed of all Nanobiotix filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Nanobiotix via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-05-11 | N/A | Other | Other | 959,060 | N/A |
